drugset
drugset / Trial / NCT05182866

ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer

NCT05182866 ↗

Phase 2 Active not recruiting 9 enrolled Rakuten Medical, Inc. National Cancer Institute (NCI) · collabShimadzu Corporation · collab
NaSingle-groupOpen-labelTreatment

Summary

A Phase 2, Open-label, Single-arm, Window of opportunity Study of ASP-1929 Photoimmunotherapy with Fluorescence Imaging in Patients with Operable Primary or Recurrent Head and Neck or Cutaneous Squamous Cell Carcinoma

Timeline

Start
2022-01-21
Primary completion
2024-07-11
Completion
2026-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject CETUXIMAB SAROTALOCAN Other / unclassified 640 mg/m2 Intravenous

Indications

head and neck squamous cell carcinoma